Bisphosphonate therapy for osteogenesis imperfecta

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2008, Pages

  Phillipi, Carrie A ^a   Remmington, Tracey ^b   Steiner, Robert D ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

AUTHOR; BONE; BONE DENSITY; BONE METABOLISM; BONE PAIN; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROL GROUP; CYSTIC FIBROSIS; DATA BASE; DATA EXTRACTION; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; FRACTURE REDUCTION; GENETIC DISORDER; GROWTH; HEALTH STATUS; HISTOLOGY; HUMAN; INCIDENCE; INTERVENTION STUDY; LUMBAR SPINE; LUNG FUNCTION; MEDLINE; MINERAL METABOLISM; OSTEOGENESIS IMPERFECTA; OUTCOME ASSESSMENT; POPULATION; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SCIENTIFIC LITERATURE; SCORING SYSTEM; TREATMENT DURATION;

EID: 55049132015     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005088.pub2     Document Type: Review

References (40)

1. Adami 2003 {published and unpublished data} * Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, et al.Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research 2003;18(1):126-30.
2. Gatti D, Viapiana O, Lippolis I, Braga V, Prizzi R, Rossini M, et al.Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research 2005;20(8):1323-6.
3. Chevrel 2006 {published data only} Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G, Duboeuf F, et al.Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.. Journal of Bone and Mineral Research 2006;21(2):300-6.
4. DiMeglio 2006 {published data only} Dimeglio LA, Ford L, McClintock C, Peacock M. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism 2005;18(1):43-53.
5. * DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research 2006;21(1):132- 40.
6. Gatti 2005 {published and unpublished data} Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tato L, et al.Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research 2005;20(5):758-63.
7. Glorieux 2004 {published data only} Glorieux FH, Rauch F, Ward LM, Smith P, Verbruggen N, Heyden N, et al.Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research 2004;20(Suppl):1043.
8. Letocha 2005 {published data only} Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, et al.Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. Journal of Bone and Mineral Research 2005;20(6):977-86.
9. Sakkers 2004 {published data only} Sakkers R, Kok D, Engelbert R, Van Dongen A, Jansen M, Pruijs H, et al.Skeletal effects and functiona outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 2004;363(9419): 1427-31.
10. Seikaly 2005 {published data only} Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D, Browne R, et al.Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics 2005;25(6):786-91.
11. Antoniazzi 1996 {published data only} Antoniazzi F, Bertoldo F, Mottes M, Valli M, Sirpresi S, Zamboni G, et al.Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. Journal of Pediatrics 1996;129(3):432-9.
12. Antoniazzi 2006 {published data only} Antoniazzi F, Zamboni G, Lauriola S, Donadi L, Adami S, Tato L. Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. Journal of Pediatrics 2006;149(2):174-9.
13. DiMeglio 2004 {published data only} DiMeglio LA, Ford L, McClintock C, Peacock M. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 2004;35(5):1038- 45.
14. Gerber 1998 {published data only} Gerber LH, Binder H, Berry R, Siegel KL, Kim H, Weintrob J, et al.Effect of withdrawal of bracing in matched pairs of children with osteogenesis imperfecta. Archives of Physical Medicine and Rehabilitation 1998;79(1):46-51.
15. Granda 1977 {published data only} Granda JL, Falva KA, Bullough PG. Phyrophosphate levels and magnesium oxide therapy in osteogenesis imperfecta. Clinical Orthopaedics and Related Research 1977;Jul-Aug(216):228-31.
16. Ward 2005 {published data only} Ward LM, Denker AE, Porras A, Shugarts S, Kline W, Travers R, et al.Single-dose pharmacokinetics and tolerability of alendronate 35-and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. Journal of Clinical Endocrinology and Metabolism 2005;90(7):4051-6.
17. Teriparatide 2008 {unpublished data only} A study to assess the effectiveness of teriparatide (FORTEO) for increasing bone mass and improving bone structure in adults affected with OI.Study ID numbers: IBMD-OI.ClinicalTrials.gov identifier NCT00063479.. Ongoing study 05/03/2005..
18. Zoledronic Acid 2008 {unpublished data only} Bisphosphonate treatment of OI.Study ID numbers: CZOL446H2202.ClinicalTrials.gov identifier NCT00063479.. Ongoing study June 2003..
19. Black 1996 Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al.Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348(9041):1535-41.
20. Byers 1991 Byers PH, Wallis GA, Willing MC. Osteogenesis imperfecta: translation of mutation to phenotype. Journal of Medical Genetics 1991;28(7):433-42.
21. Byers 1992 Byers PH, Steiner RD. Osteogenesis imperfecta. Annual Review of Medicine 1992;43:269-82.
22. Byers 2000 Byers PH. Osteogenesis imperfecta: perspectives and opportunities. Current Opinion in Pediatrics 2000;12(6):603-9.
23. Camacho 2001 Camacho NP, Raggio CL, Doty SB, Root L, Zraick V, Ilg WA, et al.A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcified Tissue International 2001;69(2):94-101.
24. Cole 2002 Cole WG. Advances in Osteogenesis Imperfecta. Clinical Orthopaedics and Related Research 2002;401:6-16.
25. Connor 1985 Connor JM, Connor RA, Sweet EM, Gibson AA, Patrick WJ, McNay MB, et al.Lethal neonatal chondrodysplasias in the West of Scotland 1970-1983 with a description of a thanatophoric, dysplasia-like, autosomal recessive disorder, Glasgow variant. American Journal of Medical Genetics 1985;22(2):243-53.
26. Elbourne 2002 Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
27. Fisher 1999 Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, et al.Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro [abstract]. Proceedings of the National Academy of Sciences of the United States of America 1999;96:133-8.
28. Glorieux 1998 Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. New England Journal of Medicine 1998;339(14):947-52.
29. Glorieux 2000 Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, et al.Type V osteogenesis imperfecta: a new form of brittle bone disease. Journal of Bone and Mineral Research 2000;15(9):1650-8.
30. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557- 60.
31. Jüni 2001 Jüni T, Altman, DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
32. Kuurila 2002 Kuurila K, Kaitila I, Johansson R, Grenman R. Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey. The Annals of Otology, Rhinology, and Laryngology 2002;111(10): 939-46.
33. Marini 2003 Marini JC. Do bisphosphonates make children's bones better or brittle?. New England Journal of Medicine 2003;349(5): 423-6.
34. OIF 2008 Osteogenesis Imperfecta Foundation. Facts about Osteogenesis Imperfecta. www.oif.org (accessed August 2008).
35. Orioli 1995 Orioli IM, Castilla EE, Scarano G, Mastroiacovo P. Effect of paternal age in achondroplasia, thanatophoric dysplasia, and osteogenesis imperfecta. American Journal of Medical Genetics 1995;59(2):209-17.
36. Reid 2002 Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al.Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New England Journal of Medicine 2002;346(9):653-61.
37. Sillence 1979 Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. Journal of Medical Genetics 1979;16(2):101-16.
38. Steiner 2005 Steiner RD, Pepin MG, Byers PH. Gene Reviews; Osteogenesis Imperfecta. www.genetests.org (accessed 28 January 2005).
39. Thornton 2006 Thornton J, Ashcroft DM, Mughal MZ, Elliott RA, O'Neill TW, Symmons D. Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis. Archives of Disease in Childhood 2006;91(9):753-61.
40. Whyte 2003 Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. New England Journal of Medicine 2003;349(5):457-63.